Parexel, a clinical research organization (CRO) providing the full range of Phase I to IV clinical development services, has appointed Charlotte Moser, MD, PhD, MBA as Chief Medical Officer.

As Chief Medical Officer, Moser will provide medical and scientific leadership globally, building on the company’s regulatory and therapeutic expertise with a significant focus on innovative drug development strategies and clinical trial design.

“We’re thrilled to welcome Dr. Moser to Parexel,” said Peyton Howell, CEO. “As a clinician, she embodies Parexel’s dedication to keeping patients at the heart of everything we do. Additionally, her unique perspectives as a biotech leader and practicing oncologist — along with her proven track record in delivery of clinical trials around the globe — will be invaluable to our team and customers as we continue to accelerate the delivery of life-changing therapies to patients.”

With more than 25 years of experience in the life sciences industry, Moser brings a unique combination of strategic clinical development leadership as well as experience as a principal investigator.

Moser has served as head of clinical development at biotechnology and life sciences companies, bringing her clinical expertise to the early development of targeted oncology diagnostics and therapeutics and working closely with global regulators to support the approval of new therapies. Her ability to drive drug and medical device strategy and development makes her well-suited to lead Parexel’s diverse portfolio of clinical research services across a broad range of therapeutic areas.

“I’m delighted to join an organization at the forefront of patient-focused drug development and healthcare innovation, with differentiated expertise in meeting the needs of life sciences customers worldwide,” said Moser. “I look forward to working with our global expert team on programs in different countries and across specific patient and local healthcare needs — all with the goal of supporting our customers in the development of ground-breaking therapies for patients.”